Loading...
•
Sep 30, 2021
Intra-Cellular Q3 2021 Earnings Report
Intra-Cellular Therapies reported a net loss of $76.9 million and total revenues of $22.2 million, with CAPLYTA net product revenues reaching $21.6 million. The company is progressing with bipolar depression launch preparations and advancing its development programs.
Key Takeaways
Intra-Cellular Therapies announced its Q3 2021 financial results, reporting a net loss of $76.9 million. Total revenues were $22.2 million, driven by CAPLYTA net product revenues of $21.6 million. The company continues to advance its development programs and prepare for the potential launch of CAPLYTA in bipolar depression.
Total revenues reached $22.2 million, a 200% increase compared to the same period last year.
CAPLYTA net product revenues were $21.6 million.
CAPLYTA total prescriptions increased 15% versus the previous quarter.
Bipolar depression launch preparations are progressing well, with sales force expansion substantially complete.
Forward Guidance
The company is focused on commercializing CAPLYTA, advancing its development programs, and preparing for the potential launch of CAPLYTA in bipolar depression.
Positive Outlook
- Progress in commercialization of CAPLYTA in schizophrenia.
- Advancement of development programs.
- Bipolar depression launch preparations are progressing well.
- Sales force expansion is substantially complete.
- Potential FDA approval of CAPLYTA for bipolar depression.
Challenges Ahead
- Uncertainties regarding FDA approval of sNDAs.
- Potential delays or challenges in commercializing CAPLYTA.
- Negative impact of COVID-19 pandemic on commercial plans and sales.
- Risks associated with clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...